ARID1B在三阴性乳腺癌中的表达及其临床意义

目的 探讨AT富集结构域蛋白1B（ARID1B）在三阴性乳腺癌（TNBC）中的表达情况及其临床意义。方法 通过免疫组化法检测ARID1B在TNBC、非TNBC及癌旁正常组织中的表达差异，并分析其表达与TNBC临床病理特征及预后的关系。结果 ARID1B在120 例乳腺癌组织和30例癌旁正常乳腺组织中的阳性表达率分别为57.5％（69／120）、13.3％（4／30），差异有统计学意义（P＜0.001）。ARID1B在90例TNBC组织中的阳性表达率为61.1％（55／90），在30例非TNBC组织中的阳性表达率为33.3％（10／30），差异亦有统计学意义（P=0.007）。TNBC患者ARID1B的表达与年龄、肿瘤大小、组织学分级及Ki-67增殖指数密切相关（P＜0.05），而与淋巴结转移、TNM分期、p53表达均无关（P＞0.05）。生存分析显示ARID1B高表达TNBC患者的中位生存时间（OS）为27.9个月（95％CI：25.1～30.8个月），显著低于低表达者的49.1个月（95％CI：40.2～57.9个月），差异有统计学意义（P=0.009）。结论 ARID1B在TNBC中高表达且与年龄、肿瘤大小、组织学分级、Ki-67指数及生存时间密切相关，其有可能是TNBC预后评估和治疗的有效生物标志物。

The expression of ARID1B in triple negative breast cancer and its clinical significance

ObjectiveTo investigate the expression levels of AT-rich interactive domain-containing protein 1B（ARID1B） in triple negative breast cancer（TNBC） and its clinical significance. Methods The expression status of ARID1B in TNBC， non-TNBC and adjacent normal tissues was detected by immunohistochemistry and the correlation between the expression levels and clinicopathological characteristics and prognosis in patients with TNBC was analyzed. Results ARID1B protein expression was higher in 150 breast cancer tissues as compared to 30 adjacent normal tissues（57.5％ vs. 13.3％， P＜0.001）. The positive expression rate of ARID1B in 90 TNBC and 30 non-TNBC group were 61.1％（55／90）and 33.3％（10／30）， respectively， with a significant difference（P=0.007）. The expression levels of ARID1B were remarkably associated with age， tumor size， histological grade and Ki-67 index（P＜0.05）， while not related to lymph node metastasis， TNM stage and the expression of p53（P＞0.05） in TNBC. Particularly， compared to low-grade tumors， ARID1B displayed more bounteously expression in high-grade TNBC（P＜0.001）. The median overall survival（OS） time in TNBC patients with high ARID1B expression was 27.9 months（95％CI：25.1-30.8 months）， lower than 49.1 months（95％CI：40.2-57.9 months）of TNBC patients with low ARID1B expression（P＜0.05）. Conclusion ARID1B is highly expressed in TNBC and its expression is significantly associated with age， tumor size， histological grade， Ki-67 index and survival， which might serve as a promising biomarker for TNBC prognostic evaluation and treatment.